Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

(2019) Ken Masuda et al.   BMC CANCER

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

(2019) Robert J Motzer et al.   LANCET ONCOLOGY

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

(2019) Brian I. Rini et al.   Journal for ImmunoTherapy of Cancer

Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma

(2018) Michael B. Atkins et al.   CANCER TREATMENT REVIEWS

Updates to the Management of Kidney Cancer

(2018) Eric Jonasch   Journal of the National Comprehensive Cancer Network

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab

(2018) Yukihiro Toi et al.   ONCOLOGIST

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

The Current and Evolving Landscape of First‐Line Treatments for Advanced Renal Cell Carcinoma

(2018) Emiliano Calvo et al.   ONCOLOGIST

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

(2015) Martina Sanlorenzo et al.   JAMA Dermatology

Development and Initial Validation of the NCCN/FACT Symptom Index for Advanced Kidney Cancer

(2013) Nan E. Rothrock et al.   VALUE IN HEALTH

A Comparison of the Renal Cell Carcinoma–Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI)

(2009) Deepa Rao et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT